|
시장보고서
상품코드
2008892
고인산혈증 치료제 시장 보고서 : 제품별, 제형별, 유통 채널별, 지역별(2026-2034년)Hyperphosphatemia Drugs Market Report by Product, Dosage Form, Distribution Channel, and Region 2026-2034 |
||||||
세계의 고인산혈증 치료제 시장 규모는 2025년에 47억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 84억 달러에 달하고, 2026년부터 2034년까지 CAGR 6.45%로 성장할 것으로 예측했습니다. 말기 신장질환(ESKD)의 유병률 증가, 만성질환에 취약한 고령 인구의 현저한 증가, 그리고 건강 인식의 증가로 인한 조기 진단 추세의 강화 등이 시장을 견인하는 주요 요인으로 작용하고 있습니다.
고인산혈증은 인의 섭취 증가, 인의 세포 외 이동, 인의 배설 감소로 인해 혈중 인 농도가 상승하는 것이 특징입니다. 고인산혈증은 만성 신장질환, 당뇨병성 케톤산증, 조절이 잘 안 되는 당뇨병, 부갑상선호르몬(PTH) 수치가 낮은 사람들에게서 자주 나타납니다. 고인산혈증 치료제에는 종종 인산염 결합제가 포함되어 있으며, 이는 혈중 고인산 농도를 조절하는 데 도움이 됩니다. 또한, 고인혈증 치료제는 소화관에서 인의 흡수를 억제하는 효과가 있습니다. 이 약제들은 인산 이온을 탄산 이온, 아세트산 이온, 수산화 이온 또는 구연산 이온과 같은 활성 양이온과 교환하여 흡수되지 않고 배설되는 화합물을 형성합니다.
고인산혈증 치료제 시장 동향:
만성 신장병(CKD)의 발병률 증가
만성 신장병(CKD)의 유병률이 전 세계적으로 증가하고 있는 것은 고인산혈증 치료제 시장 규모 확대에 기여하는 주요 트렌드입니다. CKD가 진행됨에 따라 환자는 일반적으로 인 배설 기능 장애로 인해 고인산혈증을 앓고 있습니다. 그 결과, 인산 수치를 정상 범위로 유지하기 위해 인산 결합제에 대한 수요가 증가하고 있습니다. 또한, CKD의 주요 원인인 고혈압과 당뇨병이 전 세계적으로 증가하고 있으며, 고령화 사회가 진행됨에 따라 고인산혈증 치료제 시장 확대가 가속화되고 있습니다. 또한, CKD 환자 수가 크게 증가함에 따라 고인산혈증에 대한 효율적인 관리의 필요성이 증가하고 있으며, 이는 시장 성장을 촉진하고 있습니다. 2024년 4월 학술지 'Nature Reviews Nephrology'에 게재된 연구 논문에 따르면, 전 세계적으로 약 8억 5,000만 명이 신장질환을 앓고 있습니다. 또한, CKD는 2040년까지 5번째로 많은 손실 수명(YLL)의 원인이 될 것으로 예상됩니다.
인산 결합제의 혁신
보다 효율적이고 새로운 인 결합제 제제 개발은 세계 고인산혈증 치료제 시장 규모 확대에 큰 영향을 미치는 또 다른 중요한 추세입니다. 비칼슘계 인 결합제와 같은 의약품 개발의 발전은 특히 고칼슘혈증의 위험을 최소화하는 측면에서 고인산혈증 치료 효과를 크게 향상시키고 있습니다. 예를 들어, 2023년 12월 Journal of Clinical Medicine에 게재된 연구에 따르면, 가장 널리 사용되는 비칼슘계 인 결합제인 세베라머가 CKD(만성 신장병) 4기 또는 5기 환자에게 큰 이점을 제공한다는 사실이 밝혀졌습니다. 이 약은 심혈관 사망을 63%, 모든 원인에 의한 사망을 56% 감소시켜 환자의 예후를 개선하는 데 탁월한 효과를 보였습니다. 또한, 이러한 혁신은 기존 인산염 결합제와 관련된 주요 문제를 해결하고 약물 순응도 및 환자 결과를 개선합니다. 또한, 부작용을 최소화하면서 보다 효과적인 약물이 개발되고 있다는 점은 많은 의료 종사자들의 관심을 끌고 있으며, 그 결과 채택률이 높아져 신흥국과 선진국 모두에서 시장 확대에 크게 기여하고 있습니다.
고인산혈증에 대한 인식 및 진단 개선
고인산혈증과 그 합병증에 대한 인식이 높아지면서, 특히 CKD 환자를 치료하는 의료진들 사이에서 고인산혈증과 그 합병증에 대한 인식이 높아진 것이 시장 성장에 크게 기여하고 있습니다. 고인산혈증에 대한 조기 진단 및 선별 검사의 개선은 주로 인 저하 요법에 대한 수요를 주도하고 있습니다. 또한, 의료기관의 교육 프로그램과 CKD 관련 질환에 대한 보다 전략적인 접근이 결합되어 고인산혈증에 대한 조기 치료를 촉진하고 있습니다. 또한, 고인산혈증 환자가 증가함에 따라 진단 수단에 대한 수요가 증가하고 있습니다. 2023년 5월 학술지 메디치나(Medicina)에 게재된 연구 논문에 따르면, 고인산혈증은 CKD와 관련된 가장 흔한 질환으로 신장질환 환자의 약 50-70%에게 영향을 미칩니다. 이러한 추세에 더해 신흥 지역의 첨단 의료 인프라의 발전이 더해져 고인산혈증 치료에 대한 접근성이 더욱 확대되면서 세계 시장의 전반적인 성장을 견인하고 있습니다. 업계 보고서에 따르면, 탄탄한 의료 인프라를 갖춘 주요 신흥 경제국인 중국에서는 의료비가 크게 확대되어 2023년 공공 자금이 약 3,079억 달러에 달할 것으로 예상했습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 고인산혈증 치료제 시장
제6장 시장 내역 : 제품별
제7장 시장 내역 : 제형별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 지역별
제10장 촉진요인, 억제요인, 기회
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSM 26.05.11The global hyperphosphatemia drugs market size reached USD 4.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 8.4 Billion by 2034, exhibiting a growth rate (CAGR) of 6.45% during 2026-2034. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.
Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.
HYPERPHOSPHATEMIA DRUGS MARKET TRENDS:
Increasing Incidents of Chronic Kidney Disease (CKD)
The global escalation in prevalence of chronic kidney disease (CKD) is a major trend contributing to the expansion of the hyperphosphatemia drugs market size. With the progression of CKD, patients generally suffer from hyperphosphatemia due to defective phosphate excretion. Consequently, this condition results in an elevated requirement for phosphate-binding medicines to balance the phosphate levels. Furthermore, the magnification of aging population and growing cases of hypertension and diabetes worldwide, which are major causes of CKD, are supporting the expanding market for hyperphosphatemia treatments. In addition, as the CKD patient population grows significantly, so does the demand for efficient management of hyperphosphatemia, thereby propelling market growth. According to a research article published in the journal Nature Reviews Nephrology in April 2024, around 850 million individuals globally are living with kidney disease. Additionally, CKD is anticipated to become the 5th leading cause of years of life lost (YLL) by the year 2040.
Innovations in Phosphate Binder Medications
The formulation of more efficient and newer phosphate binders is another key trend significantly impacting the expansion of global hyperphosphatemia drugs market size. Advancements in drug development, like non-calcium-based phosphate binders, have notably enhanced the treatment efficacy of hyperphosphatemia, especially in minimizing the risks of hypercalcemia. For instance, a study published in the Journal of Clinical Medicine in December 2023 revealed that sevelamer, most used non-calcium-based phosphate binder, has significant benefits for patients suffering with stage 4 or 5 CKD. This drug is associated with a 63% reduction in cardiovascular mortality and 56% reduction in all-cause mortality, highlighting its exceptional efficacy in enhancing patient outcomes. Moreover, such innovation acknowledges major concerns associated to conventional phosphate binders, providing improved adherence and patient outcomes. In addition, the production of more effective drugs with minimal side effects is appealing several healthcare professionals, resulting in an elevated rate of adoption, and substantially contributing to the market expansion in emerging as well as developed regions.
Rising Awareness and Diagnosis of Hyperphosphatemia
Growing awareness of hyperphosphatemia and its complications, particularly among healthcare providers treating CKD patients, is significantly contributing to market growth. Early diagnosis and improved screening of hyperphosphatemia are chiefly propelling the demand for phosphate-lowering therapies. Moreover, educational programs by healthcare organizations, coupled with more strategic approaches to tackle CKD-related conditions, are facilitating the early treatment of hyperphosphatemia. Furthermore, the rising case of hyperphosphatemia is spurring the demand for diagnosis options. According to a research article published in the journal Medicina in May 2023, hyperphosphatemia is the most prevailing CKD-associated disorder, impacting around 50%-70% of renal disorders patients. This trend, combined with advanced healthcare infrastructure in emerging regions, is further extending access to hyperphosphatemia treatment and fueling the overall growth of the global market. According to industry reports, China, a major emerging economy with robust healthcare infrastructure, witnessed significant expansion in healthcare expenditure, with public funding rising to around $307.9 billion in 2023.
HYPERPHOSPHATEMIA DRUGS MARKET SEGMENTATION:
Product Insights:
- Sevelamer
- Calcium Based Phosphate Binders
- Iron Based Phosphate Binders
- Lanthanum Carbonate
- Others
Dosage Form Insights:
- Tablets
- Syrups
- Capsules
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hyperphosphatemia drugs. Some of the factors driving the hyperphosphatemia drugs market share in North America includes the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
- Ardelyx Inc.
- Fresenius Medical Care AG & Co. KGaA
- Lupin Pharmaceuticals Inc (Lupin Limited)
- Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
- Vifor Pharma Management Ltd. (CSL Limited)
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. How big is the hyperphosphatemia drugs market?
2. What is the future outlook of the hyperphosphatemia drugs market?
3. What are the key factors driving the hyperphosphatemia drugs market?
4. Which region accounts for the largest hyperphosphatemia drugs market share?
5. Which are the leading companies in the global hyperphosphatemia drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Hyperphosphatemia Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Sevelamer
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Calcium Based Phosphate Binders
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Iron Based Phosphate Binders
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Lanthanum Carbonate
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Dosage Form
- 7.1 Tablets
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Syrups
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Capsules
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Ardelyx Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.2 Fresenius Medical Care AG & Co. KGaA
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Lupin Pharmaceuticals Inc (Lupin Limited)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 Vifor Pharma Management Ltd. (CSL Limited)
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.1 Ardelyx Inc.
